Clinical Trials Browser

Expanded_access × Lung Neoplasms × Thoracic × Clear all

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03756311 2026-01-23

Expanded Access to NanoPac

Lung Neoplasms, Prostatic Neoplasms

NCT06841874 2025-12-24

Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing

Thoracic

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

No longer available

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Approved for marketing

Thoracic

Lung Neoplasms

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Approved for marketing

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

No longer available

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Clinical Trials

Managed Access Programs for INC280, Capmatinib

Expanded Access to NanoPac

Tale EAP

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Early Access Program of Lazertinib in Republic of Korea

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer